Enlivex Therapeutics Ltd (ENLV) - Net Assets
Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) has net assets worth ILA17.48 Million ILA (≈ $46.87K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA20.94 Million ≈ $56.13K USD) and total liabilities (ILA3.46 Million ≈ $9.27K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Enlivex Therapeutics Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA17.48 Million |
| % of Total Assets | 83.49% |
| Annual Growth Rate | 61.49% |
| 5-Year Change | -33.53% |
| 10-Year Change | 31.55% |
| Growth Volatility | 2005.73 |
Enlivex Therapeutics Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Enlivex Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Enlivex Therapeutics Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Enlivex Therapeutics Ltd (2012–2024)
The table below shows the annual net assets of Enlivex Therapeutics Ltd from 2012 to 2024. For live valuation and market cap data, see Enlivex Therapeutics Ltd (ENLV) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA23.59 Million ≈ $63.24K |
-21.59% |
| 2023-12-31 | ILA30.08 Million ≈ $80.65K |
-47.07% |
| 2022-12-31 | ILA56.84 Million ≈ $152.39K |
-33.16% |
| 2021-12-31 | ILA85.04 Million ≈ $227.99K |
+139.63% |
| 2020-12-31 | ILA35.49 Million ≈ $95.14K |
+214.55% |
| 2019-12-31 | ILA11.28 Million ≈ $30.25K |
+16.24% |
| 2018-12-31 | ILA9.71 Million ≈ $26.02K |
+206.96% |
| 2017-12-31 | ILA3.16 Million ≈ $8.48K |
-63.65% |
| 2016-12-31 | ILA8.70 Million ≈ $23.32K |
-51.49% |
| 2015-12-31 | ILA17.93 Million ≈ $48.08K |
-41.54% |
| 2014-12-31 | ILA30.67 Million ≈ $82.24K |
+452.19% |
| 2013-12-31 | ILA5.55 Million ≈ $14.89K |
+7306.67% |
| 2012-12-31 | ILA75.00K ≈ $201.07 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Enlivex Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12687800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA2.69 Million | 11.38% |
| Other Comprehensive Income | ILA1.10 Million | 4.67% |
| Other Components | ILA146.91 Million | 622.79% |
| Total Equity | ILA23.59 Million | 100.00% |
Enlivex Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Enlivex Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Purple Biotech Ltd
TA:KTOV
|
$461.41K |
|
ProPhase Labs Inc
NASDAQ:PRPH
|
$463.75K |
|
MOVEBYBIKE EUROPE AB
F:6ZR
|
$464.77K |
|
Time Finance PLC
LSE:TIME
|
$465.71K |
|
SECITS Holding AB (publ)
ST:SECI
|
$458.10K |
|
iQ International AG
F:IQL
|
$451.96K |
|
CELLECTAR NEW22 DL-00001
F:NV4
|
$451.63K |
|
Aberdeen Diversified Income and Growth Trust PLC
LSE:ADIG
|
$450.86K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enlivex Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,084,000 to 23,589,000, a change of -6,495,000 (-21.6%).
- Net loss of 15,014,000 reduced equity.
- New share issuances of 6,452,000 increased equity.
- Other factors increased equity by 2,067,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-15.01 Million | -63.65% |
| Share Issuances | ILA6.45 Million | +27.35% |
| Other Changes | ILA2.07 Million | +8.76% |
| Total Change | ILA- | -21.59% |
Book Value vs Market Value Analysis
This analysis compares Enlivex Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2611.93x to 0.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | ILA0.00 | ILA0.72 | x |
| 2013-12-31 | ILA0.02 | ILA0.72 | x |
| 2014-12-31 | ILA0.10 | ILA0.72 | x |
| 2015-12-31 | ILA0.05 | ILA0.72 | x |
| 2016-12-31 | ILA0.02 | ILA0.72 | x |
| 2017-12-31 | ILA0.01 | ILA0.72 | x |
| 2018-12-31 | ILA2.77 | ILA0.72 | x |
| 2019-12-31 | ILA1.30 | ILA0.72 | x |
| 2020-12-31 | ILA2.69 | ILA0.72 | x |
| 2021-12-31 | ILA4.76 | ILA0.72 | x |
| 2022-12-31 | ILA3.09 | ILA0.72 | x |
| 2023-12-31 | ILA1.62 | ILA0.72 | x |
| 2024-12-31 | ILA1.15 | ILA0.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enlivex Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -63.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-63.65%) is above the historical average (-92.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -305.33% | 0.00% | 0.00x | 2.08x | ILA-236.50K |
| 2013 | -20.61% | 0.00% | 0.00x | 1.02x | ILA-1.70 Million |
| 2014 | -22.89% | 0.00% | 0.00x | 1.07x | ILA-10.09 Million |
| 2015 | -85.68% | 0.00% | 0.00x | 1.14x | ILA-17.16 Million |
| 2016 | -184.18% | 0.00% | 0.00x | 1.22x | ILA-16.89 Million |
| 2017 | -188.01% | 0.00% | 0.00x | 1.15x | ILA-6.26 Million |
| 2018 | -43.70% | 0.00% | 0.00x | 1.14x | ILA-5.21 Million |
| 2019 | -83.18% | 0.00% | 0.00x | 1.56x | ILA-10.51 Million |
| 2020 | -33.32% | 0.00% | 0.00x | 1.14x | ILA-15.37 Million |
| 2021 | -17.01% | 0.00% | 0.00x | 1.12x | ILA-22.97 Million |
| 2022 | -54.64% | 0.00% | 0.00x | 1.19x | ILA-36.74 Million |
| 2023 | -96.62% | 0.00% | 0.00x | 1.22x | ILA-32.08 Million |
| 2024 | -63.65% | 0.00% | 0.00x | 1.17x | ILA-17.37 Million |
Industry Comparison
This section compares Enlivex Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $76,467,333
- Average return on equity (ROE) among peers: -104.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enlivex Therapeutics Ltd (ENLV) | ILA17.48 Million | -305.33% | 0.20x | $458.60K |
| BioLine RX Ltd (BLRX) | $13.22 Million | -458.40% | 3.83x | $9.10 Million |
| BioLight Life Sciences Ltd (BOLT) | $40.17 Million | -29.19% | 0.06x | $7.66 Million |
| Bonus Biogroup (BONS) | $-13.72 Million | 0.00% | 0.00x | $123.99 Million |
| Can Fite Biopharma Ltd (CANF) | $2.07 Million | 0.00% | 0.31x | $5.56 Million |
| Clal Biotechnology Industries Ltd (CBI) | $497.85 Million | -30.96% | 0.24x | $12.61 Million |
| Compugen (CGEN) | $37.24 Million | -60.68% | 0.43x | $201.26 Million |
| DNA Biomed Solns (DNA) | $54.33 Million | 33.82% | 0.01x | $34.04 Million |
| Evogene (EVGN) | $50.31 Million | -41.26% | 0.17x | $4.88 Million |
| Kadimastem Ltd (KDST) | $6.74 Million | -355.71% | 1.17x | $22.18 Million |
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more